Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 631 to 640 of 2245 total matches.

Cobicistat (Tybost) and Combinations for HIV

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
(Prezcobix — Janssen) for treatment of HIV-1 infection. Both atazanavir and darunavir have traditionally ...
Cobicistat, a pharmacokinetic enhancer that boosts levels of some HIV drugs but has no antiretroviral activity of its own, is now available alone as Tybost (Gilead) and in fixed-dose combinations with the protease inhibitors atazanavir (Evotaz — BMS) and darunavir (Prezcobix — Janssen) for treatment of HIV-1 infection. Both atazanavir and darunavir have traditionally been used in combination with the CYP3A inhibitor ritonavir (Norvir) to boost their serum concentrations, but neither is available in a fixed-dose combination with ritonavir.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):159-60 | Show Introduction Hide Introduction

A Sumatriptan Patch (Zecuity) for Migraine

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015  (Issue 1481)
of suma triptan peak at a median of 1.1 hours after application of the Zecuity patch. Cmax and AUC values ...
The FDA has approved a sumatriptan iontophoretic transdermal system (Zecuity – Teva) for acute treatment of migraine in adults. Sumatriptan, the first of seven serotonin receptor antagonists (triptans) approved for this indication, is the most frequently prescribed migraine treatment in the US. It is also available in oral, intranasal, and injectable formulations.
Med Lett Drugs Ther. 2015 Nov 9;57(1481):151-2 | Show Introduction Hide Introduction

Budesonide Rectal Foam (Uceris) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015  (Issue 1481)
and as oral enteric-coated tablets (Entocort EC, and generics) for treatment of Crohn’s disease.1 ...
The FDA has approved a rectal foam formulation of the corticosteroid budesonide (Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Budesonide is also available as oral extended-release tablets (also branded as Uceris) for use in patients with UC and as oral enteric-coated tablets (Entocort EC, and generics) for treatment of Crohn's disease.
Med Lett Drugs Ther. 2015 Nov 9;57(1481):154 | Show Introduction Hide Introduction

Transdermal Fentanyl (Ionsys) for Postoperative Pain

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015  (Issue 1481)
with the ITS.1 CLINICAL STUDIES — The efficacy of the fentanyl ITS was established in three randomized ...
A patient-controlled fentanyl iontophoretic transdermal system (Ionsys – The Medicines Company) is now available for short-term management of acute postoperative pain in adults requiring opioid analgesia in the hospital. Before using Ionsys, patients must be titrated to a comfortable level of analgesia with another opioid formulation.
Med Lett Drugs Ther. 2015 Nov 9;57(1481):155-6 | Show Introduction Hide Introduction

Two Long-Acting Injectable Antipsychotics for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015  (Issue 1481)
(Abilify Maintena) and paliperidone palmitate (Invega Sustenna) were approved earlier.1,2 SECOND ...
The FDA has approved two new long-acting injectable formulations of second-generation antipsychotics for treatment of schizophrenia: aripiprazole lauroxil (Aristada – Alkermes), which is given once every 4-6 weeks, and paliperidone palmitate (Invega Trinza – Janssen), which is given once every 3 months. Once-monthly injectable formulations of aripiprazole (Abilify Maintena) and paliperidone palmitate (Invega Sustenna) were approved earlier.
Med Lett Drugs Ther. 2015 Nov 9;57(1481):152-3 | Show Introduction Hide Introduction

In Brief: Hepatic Injury with Hepatitis C Drugs

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015  (Issue 1481)
antiviral products Viekira Pak (ombitasvir/ paritaprevir/ritonavir with dasabuvir)1 and Technivie ...
The FDA recently announced labeling changes for the combination antiviral products Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir)1 and Technivie (ombitasvir/paritaprevir/ritonavir)2 warning of a risk of serious, potentially fatal liver injury.3 Viekira Pak, approved in December 2014 for treatment of hepatitis C virus (HCV) genotype 1 infection, including patients with compensated cirrhosis, and Technivie, approved in July 2015 for treatment of HCV genotype 4 infection without cirrhosis, have been identified as "possible" or "probable" causes in 26 postmarketing cases of hepatic...
Med Lett Drugs Ther. 2015 Nov 9;57(1481):156 | Show Introduction Hide Introduction

Drugs for Hypothyroidism

   
The Medical Letter on Drugs and Therapeutics • Oct 26, 2015  (Issue 1480)
is about 1.6-1.8 mcg/kg/day. Patients with thyroid cancer taking LT4 to suppress thyroid stimulating ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine is the drug of choice.
Med Lett Drugs Ther. 2015 Oct 26;57(1480):147-50 | Show Introduction Hide Introduction

Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI

   
The Medical Letter on Drugs and Therapeutics • Oct 26, 2015  (Issue 1480)
was also significantly less frequent with cangrelor than with clopidogrel (0.8% vs 1.4%).6 Cangrelor ...
The FDA has approved cangrelor (Kengreal – The Medicines Company), an IV P2Y12 platelet inhibitor, as an adjunct to percutaneous coronary intervention (PCI) in patients who have not been pretreated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Med Lett Drugs Ther. 2015 Oct 26;57(1480):145-6 | Show Introduction Hide Introduction

In Brief: A New Albuterol Inhaler (ProAir RespiClick) for Asthma

   
The Medical Letter on Drugs and Therapeutics • Oct 26, 2015  (Issue 1480)
1480) October 26, 2015 Published by The Medical Letter, Inc. • A Nonprofit Organization Table 1 ...
The short-acting beta2-agonist albuterol sulfate is now available as a dry powder for inhalation (ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir RespiClick is the only short-acting beta2-agonist dry powder inhaler available in the US.Metered-dose inhalers (MDIs) use a hydrofluoroalkane (HFA) propellant. They require coordination of inhalation with actuation; using them with a valved holding chamber minimizes this need, but decreases portability because of the size of the chamber. Dry powder inhalers such as ProAir RespiClick, which...
Med Lett Drugs Ther. 2015 Oct 26;57(1480):150 | Show Introduction Hide Introduction

Evolocumab (Repatha) - A Second PCSK9 Inhibitor to Lower LDL-Cholesterol

   
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015  (Issue 1479)
is the second PCSK9 inhibitor to be approved in the US; alirocumab (Praluent) was approved earlier.1 ...
Evolocumab (Repatha – Amgen), a subcutaneously injected PCSK9 inhibitor, has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C). It was also approved as an adjunct to diet and other LDL-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C. Evolocumab is the second PCSK9 inhibitor to be approved in the...
Med Lett Drugs Ther. 2015 Oct 12;57(1479):140-1 | Show Introduction Hide Introduction